Jadwal Sholat

Memuat jadwal sholat…

Kedokteran & Kesehatan editorial

Open AccessOA2024

Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial

The BLING III trial randomized 7,202 critically ill sepsis patients to continuous or intermittent β-lactam infusion. Continuous infusion did not significantly reduce 90-day mortality (24.9% vs 26.8%, P=0.08) but improved clinical cure (55.7% vs 50.0%).
J. Dulhunty; S. J. Brett; J. De Waele; Dorrilyn Rajbhandari; L. Billot; M. Cotta; Joshua S. Davis; S. Finfer; Naomi E. Hammond; S. Knowles; Xiao-Qiu Liu; S. McGuinness; Jayanthi Mysore; David L. Paterson; Sandra Peake; Andrew Rhodes; Jason A. Roberts; C. Roger; Charudatt Shirwadkar; T. Starr; Colman Taylor; J. Myburgh; J. Lipman· Journal of the American Medical Association (JAMA)· 2024· DOI 10.1001/jama.2024.9779

The core problem

Sepsis remains a leading cause of mortality in critically ill patients, and timely, effective antibiotic therapy is a cornerstone of management. β-lactam antibiotics, including piperacillin-tazobactam and meropenem, exhibit time-dependent killing, where the fraction of time that free drug concentrations remain above the minimum inhibitory concentration (fT>MIC) correlates with efficacy. Continuous infusion (CI) has been proposed to optimize this pharmacodynamic target compared with intermittent infusion (II), potentially improving outcomes. However, prior studies have yielded conflicting results, and uncertainty persists regarding whether CI reduces mortality in sepsis. The BLING III trial was designed to address this gap by comparing continuous versus intermittent infusion of β-lactam antibiotics in a large, international cohort of critically ill patients with sepsis. The primary hypothesis was that continuous infusion would decrease all-cause mortality at 90 days.

Innovation

BLING III was an international, open-label, randomized clinical trial conducted in 104 intensive care units (ICUs) across Australia, Belgium, France, Malaysia, New Zealand, Sweden, and the United Kingdom. Recruitment occurred from March 26, 2018, to January 11, 2023, with follow-up completed on April 12, 2023. Eligible participants were critically ill adults (≥18 years) receiving piperacillin-tazobactam or meropenem for sepsis. Patients were randomized to receive an equivalent 24-hour dose of a β-lactam antibiotic by either continuous infusion (n=3498) or intermittent infusion (n=3533) for a clinician-determined duration or until ICU discharge. The primary outcome was all-cause mortality within 90 days after randomization. Secondary outcomes included clinical cure up to 14 days, new acquisition/colonization/infection with multiresistant organisms or Clostridioides difficile, ICU mortality, and in-hospital mortality. Among 7202 randomized participants, 7031 (97.6%) met consent requirements and were included in the primary analysis (mean [SD] age, 59 [16] years; 2423 women [35%]).
Introduction
Sepsis remains a leading cause of mortality in critically ill patients, and timely, effective antibiotic therapy is a cornerstone of management. β-lactam antibiotics, including piperacillin-tazobactam and meropenem, exhibit time-dependent killing, where the fraction of time that free drug concentrations remain above the minimum inhibitory concentration (fT>MIC) correlates with efficacy. Continuous infusion (CI) has been proposed to optimize this pharmacodynamic target compared with intermittent infusion (II), potentially improving outcomes. However, prior studies have yielded conflicting results, and uncertainty persists regarding whether CI reduces mortality in sepsis. The BLING III trial was designed to address this gap by comparing continuous versus intermittent infusion of β-lactam antibiotics in a large, international cohort of critically ill patients with sepsis. The primary hypothesis was that continuous infusion would decrease all-cause mortality at 90 days.

Why it matters

The BLING III trial did not demonstrate a statistically significant reduction in 90-day mortality with continuous compared with intermittent β-lactam infusion in critically ill patients with sepsis. However, the confidence interval around the effect estimate includes both no important effect and a clinically important benefit, suggesting that continuous infusion may still offer a mortality advantage that was not definitively established. The significant improvement in clinical cure rates with continuous infusion supports the pharmacodynamic rationale of optimized fT>MIC. The open-label design and the inclusion of two different β-lactams are potential limitations, but the large sample size and international scope enhance generalizability. These findings contribute to the ongoing debate on optimal antibiotic administration in sepsis and highlight the need for further research to identify patient subgroups most likely to benefit from continuous infusion.

Who should read this

Pembaca Research Digest dan praktisi rumpun ini.

Opening member content…